Background This report describes a real-time PCR (Q-PCR) strategy to quantify
Trypanosoma cruzi (T. cruzi) DNA in peripheral blood samples from Chagas disease …

The diagnostic and clinical aspects of congenital Chagas' disease were studied in 71
children in Buenos Aires. The children's ages ranged from 2 days to 10 years. In infants< 6 …

Objectives: This prospective study focused on the evaluation of anti-parasitic therapy in
congenital Chagas' disease, diagnosed and monitored by PCR and conventional diagnosis …

Chagas disease (CD) is a worldwide problem, with over 8 million people infected in both
rural and urban areas. CD was first described over a century ago, but only two drugs are …

Congenital transmission of Trypanosoma cruzi may occur in some or all the gestations from
a T. cruzi-infected mother. Variable rates of congenital transmission have been reported in …

BACKGROUND: Chagas disease is caused by infection with Trypanosoma cruzi. In adults,
treatment with benznidazole is associated with a high incidence of adverse drug reactions …

In 2005, the World Health Organization (WHO) recognized Chagas disease (CD;
Trypanosoma cruzi infection) as a neglected tropical disease (NTD)[1] and included it into …

During an infection the immune system produces pathogen-specific antibodies. These
antibody repertoires become specific to the history of infections and represent a rich source …

Introduction Chagas disease, caused by the parasite Trypanosoma cruzi, can lead to long
term cardiac morbidity. Treatment of children with benznidazole is effective, but no pediatric …

It is currently unknown whether treatment of Chagas disease decreases the risk of
congenital transmission from previously treated mothers to their infants. In a cohort of …